ANABREZ ANASTROZOLE FILM COATED TABLET USP 1MG [SIN16144P]

Product Info

ANABREZ ANASTROZOLE FILM COATED TABLET USP 1MG

[SIN16144P]

INDICATIONS

ANABREZ is indicated for adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer.

Treatment of advanced breast cancer in postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Efficacy has not been demonstrated in oestrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen.

DOSE AND METHOD OF ADMINISTRATION

Adults including elderly: One 1mg tablet to be taken orally once a day

Special Populations

Children: Not recommended for use in children

Renal Impairment: No dose change is recommended in patients with mild or moderate renal impairment

Hepatic Impairment: No dose change is recommended in patients with mild hepatic disease.

For early disease, the recommended duration of treatment should be 5 years.

Method of Administration
For oral use

CONTRAINDICATIONS

Anastrozole is contraindicated in:

• premenopausal women

• pregnant or lactating women

• patients with severe renal impairment (creatinine clearance less than 20ml/min)

• patients with moderate or severe hepatic disease

• patients with known hypersensitivity to anastrozole or to any of the excipients

Oestrogen-containing therapies should not be co-administered with anastrozole as they would negate its pharmacological action.

Concurrent tamoxifen therapy (see DRUG INTERACTIONS – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)